{"id": "NyCqe-QAAAAJ", "citedby": 4855, "citedby5y": 4357, "hindex": 35, "hindex5y": 30, "i10index": 67, "i10index5y": 64, "coauthors": [], "name": "Daniel Catenacci", "affiliation": "Associate Professor of Medicine", "interests": ["Gastrointestinal Oncology"], "cites_per_year": {"2007": 16, "2008": 19, "2009": 17, "2010": 23, "2011": 30, "2012": 53, "2013": 87, "2014": 191, "2015": 379, "2016": 528, "2017": 702, "2018": 901, "2019": 1178, "2020": 600}, "publications": [{"bib": {"title": "Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:g5m5HwL7SMYC", "citedby": "560"}, {"bib": {"title": "Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:L8Ckcad2t8MC", "citedby": "383"}, {"bib": {"title": "New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:CHSYGLWDkRkC", "citedby": "253"}, {"bib": {"title": "Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:HoB7MX3m0LUC", "citedby": "241"}, {"bib": {"title": "Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:isC4tDSrTZIC", "citedby": "217"}, {"bib": {"title": "Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:YOwf2qJgpHMC", "citedby": "186"}, {"bib": {"title": "Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in \u2026", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:UxriW0iASnsC", "citedby": "167"}, {"bib": {"title": "KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:hqOjcs7Dif8C", "citedby": "148"}, {"bib": {"title": "Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence", "year": "2011"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:8k81kl-MbHgC", "citedby": "122"}, {"bib": {"title": "Myelodysplasic syndromes: a comprehensive review", "year": "2005"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:_Qo2XoVZTnwC", "citedby": "120"}, {"bib": {"title": "Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised \u2026", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:d1gkVwhDpl0C", "citedby": "114"}, {"bib": {"title": "Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:3fE2CSJIrl8C", "citedby": "111"}, {"bib": {"title": "Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro \u2026", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:JV2RwH3_ST0C", "citedby": "104"}, {"bib": {"title": "Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:roLk4NBRz8UC", "citedby": "90"}, {"bib": {"title": "A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:f2IySw72cVMC", "citedby": "90"}, {"bib": {"title": "Biliary cancer: Utility of next\u2010generation sequencing for clinical management", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:_FxGoFyzp5QC", "citedby": "87"}, {"bib": {"title": "RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma", "year": "2011"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:BqipwSGYUEgC", "citedby": "85"}, {"bib": {"title": "Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:r0BpntZqJG4C", "citedby": "84"}, {"bib": {"title": "LBA15A phase 1B study of pembrolizumab (PEMBRO; MK-3475) in patients (PTS) with advanced gastric cancer", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Wp0gIr-vW9MC", "citedby": "84"}, {"bib": {"title": "Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:KlAtU1dfN6UC", "citedby": "73"}, {"bib": {"title": "Tumor genome analysis includes germline genome: are we ready for surprises?", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:P5F9QuxV20EC", "citedby": "65"}, {"bib": {"title": "Molecular profiling of cancer\u2014the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic", "year": "2011"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:mB3voiENLucC", "citedby": "62"}, {"bib": {"title": "Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in \u2026", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:nb7KW1ujOQ8C", "citedby": "61"}, {"bib": {"title": "Gastroesophageal cancer: focus on epidemiology, classification, and staging", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:sSrBHYA8nusC", "citedby": "59"}, {"bib": {"title": "Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:fPk4N6BV_jEC", "citedby": "58"}, {"bib": {"title": "Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:uWQEDVKXjbEC", "citedby": "56"}, {"bib": {"title": "Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:tS2w5q8j5-wC", "citedby": "56"}, {"bib": {"title": "Personalized colon cancer care in 2010", "year": "2011"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Tiz5es2fbqcC", "citedby": "54"}, {"bib": {"title": "Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:5ugPr518TE4C", "citedby": "46"}, {"bib": {"title": "LBA28_PRKEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:9yKSN-GCB0IC", "citedby": "43"}, {"bib": {"title": "Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with \u2026", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:O3NaXMp0MMsC", "citedby": "41"}, {"bib": {"title": "Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:kNdYIx-mwKoC", "citedby": "40"}, {"bib": {"title": "Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:KxtntwgDAa4C", "citedby": "39"}, {"bib": {"title": "Toward personalized treatment of advanced biliary tract cancers", "year": "2012"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:abG-DnoFyZgC", "citedby": "39"}, {"bib": {"title": "A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:2osOgNQ5qMEC", "citedby": "35"}, {"bib": {"title": "Differential expression of RON in small and non\u2013small cell lung cancers", "year": "2012"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:mVmsd5A6BfQC", "citedby": "32"}, {"bib": {"title": "ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:N5tVd3kTz84C", "citedby": "30"}, {"bib": {"title": "Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations.", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:4DMP91E08xMC", "citedby": "30"}, {"bib": {"title": "Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC)", "year": "2008"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:M3NEmzRMIkIC", "citedby": "29"}, {"bib": {"title": "Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:4OULZ7Gr8RgC", "citedby": "28"}, {"bib": {"title": "Next-generation companion diagnostics: promises, challenges, and solutions", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:XiSMed-E-HIC", "citedby": "28"}, {"bib": {"title": "Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:1qzjygNMrQYC", "citedby": "27"}, {"bib": {"title": "Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ \u2026", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:RGFaLdJalmkC", "citedby": "26"}, {"bib": {"title": "Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ZeXyd9-uunAC", "citedby": "25"}, {"bib": {"title": "A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic \u2026", "year": "2012"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:1sJd4Hv_s6UC", "citedby": "23"}, {"bib": {"title": "FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:9Nmd_mFXekcC", "citedby": "20"}, {"bib": {"title": "Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:j3f4tGmQtD8C", "citedby": "20"}, {"bib": {"title": "MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:4JMBOYKVnBMC", "citedby": "19"}, {"bib": {"title": "A phase II randomized trial (GO27827) of first\u2010line FOLFOX plus bevacizumab with or without the MET inhibitor onartuzumab in patients with metastatic colorectal cancer", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:GnPB-g6toBAC", "citedby": "19"}, {"bib": {"title": "LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal \u2026", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:geHnlv5EZngC", "citedby": "18"}, {"bib": {"title": "Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:zA6iFVUQeVQC", "citedby": "17"}, {"bib": {"title": "Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Tyk-4Ss8FVUC", "citedby": "16"}, {"bib": {"title": "Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:qxL8FJ1GzNcC", "citedby": "15"}, {"bib": {"title": "Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:JoZmwDi-zQgC", "citedby": "14"}, {"bib": {"title": "Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:zYLM7Y9cAGgC", "citedby": "13"}, {"bib": {"title": "A subgroup cluster\u2010based Bayesian adaptive design for precision medicine", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:IjCSPb-OGe4C", "citedby": "13"}, {"bib": {"title": "A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:4TOpqqG69KYC", "citedby": "13"}, {"bib": {"title": "Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable \u2026", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:mvPsJ3kp5DgC", "citedby": "12"}, {"bib": {"title": "Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:LkGwnXOMwfcC", "citedby": "12"}, {"bib": {"title": "Toward personalized treatment for gastroesophageal adenocarcinoma (GEC): Strategies to address tumor heterogeneity\u2014PANGEA.", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:70eg2SAEIzsC", "citedby": "12"}, {"bib": {"title": "Margetuximab plus pembrolizumab in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma post trastuzumab", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:QIV2ME_5wuYC", "citedby": "11"}, {"bib": {"title": "Update on gastroesophageal adenocarcinoma targeted therapies", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:hFOr9nPyWt4C", "citedby": "11"}, {"bib": {"title": "It is time to stop using epirubicin to treat any patient with gastroesophageal adenocarcinoma", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Zph67rFs4hoC", "citedby": "11"}, {"bib": {"title": "Expansion platform type II: testing a treatment strategy", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:p2g8aNsByqUC", "citedby": "11"}, {"bib": {"title": "A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction \u2026", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:bFI3QPDXJZMC", "citedby": "11"}, {"bib": {"title": "Novel targeted therapies for esophagogastric cancer", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:NhqRSupF_l8C", "citedby": "10"}, {"bib": {"title": "Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:eQOLeE2rZwMC", "citedby": "10"}, {"bib": {"title": "A UGT1A1 genotype\u2010guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:RYcK_YlVTxYC", "citedby": "9"}, {"bib": {"title": "Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:UebtZRa9Y70C", "citedby": "9"}, {"bib": {"title": "A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal \u2026", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ZHo1McVdvXMC", "citedby": "9"}, {"bib": {"title": "Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:7PzlFSSx8tAC", "citedby": "8"}, {"bib": {"title": "Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:9vf0nzSNQJEC", "citedby": "7"}, {"bib": {"title": "Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:wbdj-CoPYUoC", "citedby": "6"}, {"bib": {"title": "Antitumor Activity of Margetuximab plus Pembrolizumab in Patients with Advanced HER2+(IHC3+) Gastric Carcinoma", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:cFHS6HbyZ2cC", "citedby": "6"}, {"bib": {"title": "Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:qjMakFHDy7sC", "citedby": "6"}, {"bib": {"title": "Therapeutically induced changes in HER2, HER3, and EGFR protein expression for treatment guidance", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Y0pCki6q_DkC", "citedby": "6"}, {"bib": {"title": "Peri-operative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PDAC): A pilot study.", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:_xSYboBqXhAC", "citedby": "6"}, {"bib": {"title": "LBA-04 Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:u_35RYKgDlwC", "citedby": "6"}, {"bib": {"title": "A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:hC7cP41nSMkC", "citedby": "6"}, {"bib": {"title": "829 Detection of Portal Vein (PV) Circulating Tumor Cells (CTCs) in Pancreatic Cancer (PC) Patients Obtained by EUS Guided Pv Sampling. a Safety and Feasibility Trial", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ns9cj8rnVeAC", "citedby": "6"}, {"bib": {"title": "756P Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically \u2026", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:tOudhMTPpwUC", "citedby": "5"}, {"bib": {"title": "A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:-f6ydRqryjwC", "citedby": "5"}, {"bib": {"title": "Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:HE397vMXCloC", "citedby": "4"}, {"bib": {"title": "Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:olpn-zPbct0C", "citedby": "4"}, {"bib": {"title": "KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors \u2026", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:4fKUyHm3Qg0C", "citedby": "4"}, {"bib": {"title": "MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC).", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ufrVoPGSRksC", "citedby": "4"}, {"bib": {"title": "FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:SeFeTyx0c_EC", "citedby": "4"}, {"bib": {"title": "561 Development of a Quantitative Gastroesophageal Cancer Selected Reaction Monitoring Mass Spectrometric Multiplex Assay for Use in FFPE Tumor Tissues", "year": "2012"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:rO6llkc54NcC", "citedby": "4"}, {"bib": {"title": "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:URolC5Kub84C", "citedby": "3"}, {"bib": {"title": "First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:j8SEvjWlNXcC", "citedby": "3"}, {"bib": {"title": "The time for mainstreaming germline testing for patients with breast cancer is now", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Y5dfb0dijaUC", "citedby": "3"}, {"bib": {"title": "Keeping Checkpoint Inhibitors in Check", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:bnK-pcrLprsC", "citedby": "3"}, {"bib": {"title": "Variety is the spice of life, but maybe not in gastroesophageal adenocarcinomas", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:LPZeul_q3PIC", "citedby": "3"}, {"bib": {"title": "Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC)", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ULOm3_A8WrAC", "citedby": "3"}, {"bib": {"title": "662P Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:RHpTSmoSYBkC", "citedby": "3"}, {"bib": {"title": "FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated \u2026", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ldfaerwXgEUC", "citedby": "3"}, {"bib": {"title": "Circulating tumor DNA (ctDNA) landscape and prognostic implications in advanced gastroesophageal adenocarcinoma (GEC).", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:D03iK_w7-QYC", "citedby": "3"}, {"bib": {"title": "Cell free circulating tumor DNA (ctDNA) landscape in patients with advanced gastroesophageal adenocarcinoma (GEC).", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:YFjsv_pBGBYC", "citedby": "3"}, {"bib": {"title": "How can next-generation diagnostics aid pancreatic adenocarcinoma treatment?", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:SP6oXDckpogC", "citedby": "3"}, {"bib": {"title": "A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic \u2026", "year": "2012"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:YsMSGLbcyi4C", "citedby": "3"}, {"bib": {"title": "Safety and efficacy of durvalumab in combination with tremelimumab in patients with advanced gastric cancer with elevated tumor interferon-gamma gene signature", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:JQOojiI6XY0C", "citedby": "2"}, {"bib": {"title": "Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:XiVPGOgt02cC", "citedby": "2"}, {"bib": {"title": "Initial Report of Second\u2010Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi\u2010Institutional Retrospective Analysis", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:HDshCWvjkbEC", "citedby": "2"}, {"bib": {"title": "A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:NaGl4SEjCO4C", "citedby": "2"}, {"bib": {"title": "The approach to celiac disease in children", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:eJXPG6dFmWUC", "citedby": "2"}, {"bib": {"title": "Identification of T-cell-inflamed gastric adenocarcinoma in The Cancer Genome Atlas (TCGA).", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:MXK_kJrjxJIC", "citedby": "2"}, {"bib": {"title": "Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial.", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:b0M2c_1WBrUC", "citedby": "2"}, {"bib": {"title": "1106 EUS Acquired Portal Venous Circulating Tumor Cells (PV-CTCs) May Provide Prognostic Assistance in Pancreaticobiliary Cancers", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:TQgYirikUcIC", "citedby": "2"}, {"bib": {"title": "Pricinples of Multimodality Therapy", "year": "2009"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:e5wmG9Sq2KIC", "citedby": "2"}, {"bib": {"title": "Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:4MWp96NkSFoC", "citedby": "1"}, {"bib": {"title": "Evaluation of the Association of Perioperative UGT1A1 Genotype\u2013Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally \u2026", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:vDijr-p_gm4C", "citedby": "1"}, {"bib": {"title": "Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:hkOj_22Ku90C", "citedby": "1"}, {"bib": {"title": "Pemigatinib for Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:-_dYPAW6P2MC", "citedby": "1"}, {"bib": {"title": "FGFR2\u2010Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:eMMeJKvmdy0C", "citedby": "1"}, {"bib": {"title": "Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing \u2018gFOLFIRINOX\u2019for gastroesophageal adenocarcinoma (GEA).", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Mojj43d5GZwC", "citedby": "1"}, {"bib": {"title": "Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:dshw04ExmUIC", "citedby": "1"}, {"bib": {"title": "When Inhibitor MET Biomarker: Postmortem or Initium Novum?", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:q3oQSFYPqjQC", "citedby": "1"}, {"bib": {"title": "Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:_kc_bZDykSQC", "citedby": "1"}, {"bib": {"title": "Abstract A183: Blood-based genomic profiling of cell-free tumor DNA (ctDNA) in patients with biliary tract cancer", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:WbkHhVStYXYC", "citedby": "1"}, {"bib": {"title": "HER2 protein quantification in multiple cancer indications identifies candidates for HER2 targeted therapies", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:35N4QoGY0k4C", "citedby": "1"}, {"bib": {"title": "Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:nrtMV_XWKgEC", "citedby": "1"}, {"bib": {"title": "PD-007Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:WF5omc3nYNoC", "citedby": "1"}, {"bib": {"title": "Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:TFP_iSt0sucC", "citedby": "1"}, {"bib": {"title": "Quantification of HER2 from gastroesophageal cancer (GEC) FFPE tissue by mass spectrometry (MS).", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:3s1wT3WcHBgC", "citedby": "1"}, {"bib": {"title": "Development of a quantitative colorectal cancer SRM assay for use in FFPE tumor tissues.", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:k_IJM867U9cC", "citedby": "1"}, {"bib": {"title": "A survey of the population genetic variation in the human kinome", "year": "2009"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:2P1L_qKh6hAC", "citedby": "1"}, {"bib": {"title": "Message logging", "year": "2004"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:dQ2og3OwTAUC", "citedby": "1"}, {"bib": {"title": "The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ML0RJ9NH7IQC", "citedby": "0"}, {"bib": {"title": "The Chicago Consensus on peritoneal surface malignancies: Standards", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Z5m8FVwuT1cC", "citedby": "0"}, {"bib": {"title": "The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:BUYA1_V_uYcC", "citedby": "0"}, {"bib": {"title": "Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:uWiczbcajpAC", "citedby": "0"}, {"bib": {"title": "Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:uLbwQdceFCQC", "citedby": "0"}, {"bib": {"title": "Fight-202: A Phase 2 Study of Pemigatinib in Patients (PTS) with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (CCA)", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:AvfA0Oy_GE0C", "citedby": "0"}, {"bib": {"title": "Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:epqYDVWIO7EC", "citedby": "0"}, {"bib": {"title": "Cytoreductive surgery in selected patients with metastatic gastric cancer treated with systemic chemotherapy.", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:zLWjf1WUPmwC", "citedby": "0"}, {"bib": {"title": "Identification of cancer hallmarks associated with benefit in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade.", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:EkHepimYqZsC", "citedby": "0"}, {"bib": {"title": "Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013)+/-chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction \u2026", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ipzZ9siozwsC", "citedby": "0"}, {"bib": {"title": "Phase II study of trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC).", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:uc_IGeMz5qoC", "citedby": "0"}, {"bib": {"title": "Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:0KyAp5RtaNEC", "citedby": "0"}, {"bib": {"title": "Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype\u2013Guided \u2026", "year": "2020"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:5awf1xo2G04C", "citedby": "0"}, {"bib": {"title": "First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:VLnqNzywnoUC", "citedby": "0"}, {"bib": {"title": "Randomised Phase 3 Study of Ivosidenib in  IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:fEOibwPWpKIC", "citedby": "0"}, {"bib": {"title": "Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013)+/-chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:35r97b3x0nAC", "citedby": "0"}, {"bib": {"title": "HER2 is associated with prolonged survival in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:2KloaMYe4IUC", "citedby": "0"}, {"bib": {"title": "GLOW: Zolbetuximab plus CAPOX compared with placebo plus CAPOX as first-line treatment for patients with Claudin18. 2+/HER2-Locally advanced unresectable or metastatic gastric \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:z_wVstp3MssC", "citedby": "0"}, {"bib": {"title": "197TiP GLOW: Zolbetuximab+ CAPOX compared with placebo+ CAPOX as first-line treatment for patients with Claudin18. 2+/HER2\u2013Locally advanced unresectable or metastatic gastric \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ZfRJV9d4-WMC", "citedby": "0"}, {"bib": {"title": "198TiP SPOTLIGHT: Comparison of zolbetuximab or placebo+ mFOLFOX6 as first-line treatment in patients with claudin18. 2+/HER2\u2013locally advanced unresectable or metastatic \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:tKAzc9rXhukC", "citedby": "0"}, {"bib": {"title": "Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:PR6Y55bgFSsC", "citedby": "0"}, {"bib": {"title": "1188PD Margetuximab (M)+ pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:1yQoGdGgb4wC", "citedby": "0"}, {"bib": {"title": "A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:VL0QpB8kHFEC", "citedby": "0"}, {"bib": {"title": "123P Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:ye4kPcJQO24C", "citedby": "0"}, {"bib": {"title": "GLOW: Randomized phase III study of zolbetuximab+ CAPOX compared with placebo+ CAPOX as first-line treatment of patients with CLD18. 2+/HER2\u2212 locally advanced unresectable or \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:LjlpjdlvIbIC", "citedby": "0"}, {"bib": {"title": "Quantifying KRAS for Optimal Cancer Therapy", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:WqliGbK-hY8C", "citedby": "0"}, {"bib": {"title": "Obtaining Knowledge in Pathology Reports Through a Natural Language Processing Approach With Classification, Named-Entity Recognition, and Relation-Extraction Heuristics", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:PELIpwtuRlgC", "citedby": "0"}, {"bib": {"title": "Abstract CT057: Safety and efficacy of durvalumab in combination with tremelimumab in patients with advanced gastric cancer with elevated tumor interferon-\u03b3 gene signature", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:tkaPQYYpVKoC", "citedby": "0"}, {"bib": {"title": "386 HIGH NUMBERS OF PORTAL VENOUS CIRCULATING TUMOR CELLS ACQUIRED VIA EUS PROVIDE PROGNOSTIC ASSISTANCE FOR PROGRESSION FREE SURVIVAL IN PANCREATICOBILIARY CANCERS", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:AXPGKjj_ei8C", "citedby": "0"}, {"bib": {"title": "Population health impact of genome-driven oncology by race and ethnicity.", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:WA5NYHcadZ8C", "citedby": "0"}, {"bib": {"title": "Suspected and confirmed germline variants from tumor-only somatic sequencing of 864 gastrointestinal malignancies.", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:t6usbXjVLHcC", "citedby": "0"}, {"bib": {"title": "Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:_B80troHkn4C", "citedby": "0"}, {"bib": {"title": "A Comprehensive Clinicopathologic and Molecular Analysis of Early Onset Gastroesophageal Adenocarcinomas", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:SdhP9T11ey4C", "citedby": "0"}, {"bib": {"title": "Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with \u2026", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:OU6Ihb5iCvQC", "citedby": "0"}, {"bib": {"title": "Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab.", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:NMxIlDl6LWMC", "citedby": "0"}, {"bib": {"title": "AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual\u2010agent dose finding trials", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:UeHWp8X0CEIC", "citedby": "0"}, {"bib": {"title": "Global metabolomics of advanced gastric cancer patients identifies signatures associated with response and clinical benefit from nivolumab", "year": "2019"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:tzM49s52ZIMC", "citedby": "0"}, {"bib": {"title": "Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition (vol 24, pg 968, 2018)", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:yB1At4FlUx8C", "citedby": "0"}, {"bib": {"title": "A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:V3AGJWp-ZtQC", "citedby": "0"}, {"bib": {"title": "99P A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:9ZlFYXVOiuMC", "citedby": "0"}, {"bib": {"title": "Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced \u2026", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:xtRiw3GOFMkC", "citedby": "0"}, {"bib": {"title": "Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:a0OBvERweLwC", "citedby": "0"}, {"bib": {"title": "Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy.", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:B3FOqHPlNUQC", "citedby": "0"}, {"bib": {"title": "A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas.", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:dhFuZR0502QC", "citedby": "0"}, {"bib": {"title": "Safety and tolerability of 5-FU, irinotecan (IRI), and nab-paclitaxel (FOLFIRABRAX) with genotype-guided dosing of IRI in previously untreated patients with advanced \u2026", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:aqlVkmm33-oC", "citedby": "0"}, {"bib": {"title": "The Oncologist 2018; 23: e179\u2013e182 www. TheOncologist. com", "year": "2018"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:evX43VCCuoAC", "citedby": "0"}, {"bib": {"title": "146PPredicting response to chemotherapy in gastric cancer patients randomized to docetaxel: A reevaluation of the ITACA-S trial", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:lSLTfruPkqcC", "citedby": "0"}, {"bib": {"title": "Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA.", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:J_g5lzvAfSwC", "citedby": "0"}, {"bib": {"title": "Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:K3LRdlH-MEoC", "citedby": "0"}, {"bib": {"title": "HER2 Expression Is Predominantly Negative in GEJ and Gastric Adenocarcinoma with Signet Ring Cell Differentiation; Study of 346 Cases", "year": "2017"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:0EnyYjriUFMC", "citedby": "0"}, {"bib": {"title": "Updated, expanded analysis with next generation sequencing (NGS) of biliary tract cancer confirms association between tumor somatic variants and chemotherapy resistance", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:hMod-77fHWUC", "citedby": "0"}, {"bib": {"title": "KRAS Gene Amplification Defines A Distinct Molecular Subgroup of Gastroesophageal Adenocarcinoma", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:u5HHmVD_uO8C", "citedby": "0"}, {"bib": {"title": "KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.", "year": "2016"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:maZDTaKrznsC", "citedby": "0"}, {"bib": {"title": "Development and clinical validation of a quantitative mass spectrometric assay for immuno-oncology targets in FFPE samples", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:l7t_Zn2s7bgC", "citedby": "0"}, {"bib": {"title": "\ufffc A novel clinical tool that provides quantitative and accurate measurement of Met protein", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:W7OEmFMy1HYC", "citedby": "0"}, {"bib": {"title": "Anasarca and hypoalbuminaemia: case report", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:u-x6o8ySG0sC", "citedby": "0"}, {"bib": {"title": "Her2 expression in gastroesophageal cancer (GEC) FFPE tissue using mass spectrometry (MS) and correlation with HER2 gene amplification.", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:pyW8ca7W8N0C", "citedby": "0"}, {"bib": {"title": "Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer", "year": "2015"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:Se3iqnhoufwC", "citedby": "0"}, {"bib": {"title": "KRAS gene amplification is a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined RAS/RAF/MEK/ERK and PI3K/PTEN/AKT/mTOR pathway inhibition", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:fQNAKQ3IYiAC", "citedby": "0"}, {"bib": {"title": "Challenges of applying tumor genome analysis to the germline: Examples from GI oncology", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:vRqMK49ujn8C", "citedby": "0"}, {"bib": {"title": "Abstract A55: KRAS gene amplification is a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined RAS/RAF/MEK/ERK and PI3K/PTEN/AKT/mTOR \u2026", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:pqnbT2bcN3wC", "citedby": "0"}, {"bib": {"title": "537 Absolute quantitation of MET using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:dfsIfKJdRG4C", "citedby": "0"}, {"bib": {"title": "Kinase activity profiling combined with genotyping as a tool for predictive biomarker discovery for the treatment of gastroesophageal adenocarcinoma (GEC)", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:blknAaTinKkC", "citedby": "0"}, {"bib": {"title": "Quantification of MET expression using mass spectrometry (MS): Assay precision and stability in FFPE tumor tissue", "year": "2014"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:08ZZubdj9fEC", "citedby": "0"}, {"bib": {"title": "Poster session 4. Molecular diagnosis & biomarkers", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:J-pR_7NvFogC", "citedby": "0"}, {"bib": {"title": "Development of Quantitative Gastrointestinal Carcinoma (GEC and CRC) SRM Assays for Use in FFPE Tumor Tissues", "year": "2013"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:vV6vV6tmYwMC", "citedby": "0"}, {"bib": {"title": "483 Development of a Quantitative Colorectal Cancer SRM Assay for Use in FFPE Tumor Tissues", "year": "2012"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:IWHjjKOFINEC", "citedby": "0"}, {"bib": {"title": "820 Development of a Quantitative RON SRM Assay for Use in Formalin Fixed Tumor Tissues", "year": "2012"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:8AbLer7MMksC", "citedby": "0"}, {"bib": {"title": "Abstract A50: Development of a quantitative RON SRM Assay for use in formalin fixed tumor tissues", "year": "2012"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:5nxA0vEk-isC", "citedby": "0"}, {"bib": {"title": "6609 POSTER RON (MST1R) is a Novel Therapeutic Target for Gastroesophageal Adenocarcinoma", "year": "2011"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:iH-uZ7U-co4C", "citedby": "0"}, {"bib": {"title": "Abstract LB-124: RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma", "year": "2011"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:VOx2b1Wkg3QC", "citedby": "0"}, {"bib": {"title": "OFFICE ONCOLOGY", "year": "2011"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:D_sINldO8mEC", "citedby": "0"}, {"bib": {"title": "Myelodysplasic syndromes: A comprehensive"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:UHK10RUVsp4C", "citedby": "0"}, {"bib": {"title": "Our thanks to all those who have helped with this issue of Future Oncology. Listed below are authors, referees and others who have kindly given their time, effort and expertise \u2026"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:5Ul4iDaHHb8C", "citedby": "0"}, {"bib": {"title": "MET2as2a2Prognostic2Biomarker2of2Survival2in2a2Large2Cohort2of2Patients2With2Gastroesophageal2Cancer"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:yD5IFk8b50cC", "citedby": "0"}, {"bib": {"title": "Our thanks to those who have helped with this issue of Expert Review of Anticancer Therapy. Listed below are the authors, referees and others who have kindly given their time \u2026"}, "source": "citations", "id_citations": "NyCqe-QAAAAJ:M05iB0D1s5AC", "citedby": "0"}]}